A recombinant human neuregulin-1 peptide improves preservation of the rodent heart after prolonged hypothermic storage

Transplantation

Volumn 91, Issue 9, 2011, Pages 961-967

  Jabbour, Andrew ^a   Gao, Ling ^a   Kwan, Jair ^a   Watson, Alasdair ^a   Sun, Lin ^a   Qiu, Min Ru ^a   Liu, Xifu ^b   Zhou, Ming Dong ^b   Graham, Robert M ^a   Hicks, Mark ^a,c   MacDonald, Peter S ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b Zensun Sci and Tech Co (Sydney) Pty Ltd   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Apoptosis; Heart transplantation; Ischemia reperfusion injury; Neuregulin

Indexed keywords

CARIPORIDE; CASPASE 3; CELSIOR; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RECOMBINANT HUMAN NEUREGULIN 1 PEPTIDE; RECOMBINANT PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLD ISCHEMIA; CONTROLLED STUDY; CRYOPRESERVATION; ENZYME ACTIVATION; FUNCTIONAL ASSESSMENT; GRAFT SURVIVAL; HEART FUNCTION; HEART OUTPUT; HEART PRESERVATION; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION; TIME;

ANIMALS; APOPTOSIS; CARDIAC OUTPUT; COLD ISCHEMIA; DISACCHARIDES; ELECTROLYTES; GLUTAMATES; GLUTATHIONE; GUANIDINES; HEART; HEART TRANSPLANTATION; HISTIDINE; HUMANS; MALE; MANNITOL; MODELS, ANIMAL; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; NEUREGULIN-1; NITROGLYCERIN; ORGAN PRESERVATION; ORGAN PRESERVATION SOLUTIONS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SULFONES; TIME FACTORS;

EID: 79955539266     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182115b4b     Document Type: Article

References (36)

1. Daneshmand MA, Milano CA. Surgical treatments for advanced heart failure. Surg Clin North Am 2009; 89: 967.
2. Felker GM, Milano CA, Yager JEE, et al. Outcomes with an alternate list strategy for heart transplantation. J Heart Lung Transplant 2005; 24: 1781.
3. Taylor DO, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fifth official adult heart transplant report-2008. J Heart Lung Transplant 2008; 27: 943.
4. Gao L, Hicks M, Macdonald PS. Improved preservation of the rat heart with Celsior solution supplemented with cariporide plus glyceryl trinitrate. Am J Transplant 2005; 5: 1820.
5. Gao L, Kwan JC, Macdonald PS, et al. Improved poststorage cardiac function by poly (ADP-ribose) polymerase inhibition: Role of phosphatidylinositol 3-kinase Akt pathway. Transplantation 2007; 84: 380.
6. Hing AJ, Watson A, Hicks M, et al. Combining cariporide with glyceryl trinitrate optimizes cardiac preservation during porcine heart transplantation. Am J Transplant 2009; 9: 2048.
7. Mentzer RM Jr, Bartels C, Bolli R, et al. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: Results of the EXPEDITION Study. Ann Thoracic Surg 2008; 85: 1261.
8. Ryan JB, Hicks M, Cropper JR, et al. Cariporide (HOE-642) improves cardiac allograft preservation in a porcine model of orthotopic heart transplantation. Transplantation 2003; 75: 625.
9. Rohrbach S, Niemann B, Silber RE, et al. Neuregulin receptors erbB2 and erbB4 in failing human myocardium-Depressed expression and attenuated activation. Basic Res Cardiol 2005; 100: 240.
10. Garratt AN. "To erb-B or not to erb-B." Neuregulin-1/ErbB signaling in heart development and function. J Mol Cell Cardiol 2006; 41: 215.
11. Liu X, Hwang H, Cao L, et al. Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Proc Natl Acad Sci U S A 1998; 95: 13024.
12. Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995; 378: 390.
13. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8: 459.
14. Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998; 273: 10261.
15. Sawyer DB, Zuppinger C, Miller TA, et al. Modulation of anthracyclineinduced myofibrillar disarray in rat ventricular myocytes by neuregulin- 1{beta} and anti-erbB2: Potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002; 105: 1551.
16. Bersell K, Arab S, Haring B, et al. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009; 138: 257.
17. Liu X, Gu XH, Li Z, et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 2006; 48: 1438.
18. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: Targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004; 61: 448.
19. Boengler K, Buechert A, Heinen Y, et al. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 2008; 102: 131.
20. Lecour S, Suleman N, Deuchar GA, et al. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 2005; 112: 3911.
21. Suleman N, Somers S, Smith R, et al. Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. Cardiovasc Res 2008; 79: 127.
22. Lacerda L, Somers S, Opie LH, et al. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 2009; 84: 201.
23. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J Mol Cell Cardiol 2009; 47: 32.
24. Lecour S. Multiple protective pathways against reperfusion injury: A SAFE path without Aktion? J Mol Cell Cardiol 2009; 46: 607.
25. Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: Its contribution to ischemic preconditioning. Cardiovasc Res 2004; 63: 305.
26. Heusch G, Boengler K, Schulz R. Cardioprotection: Nitric oxide, protein kinases, and mitochondria. Circulation 2008; 118: 1915.
27. Piper HM, Kasseckert S, Abdallah Y. The sarcoplasmic reticulum as the primary target of reperfusion protection. Cardiovasc Res 2006; 70: 170.
28. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124.
29. Heusch G. Postconditioning: Old wine in a new bottle? J Am Coll Cardiol 2004; 44: 1111.
30. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285: H579.
31. Heusch G. No risk, no cardioprotection? A critical perspective. Cardiovasc Res 2009; 84: 173.
32. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: Underlying mechanisms and clinical application. Atherosclerosis 2009; 204: 334.
33. Pinsky DJ, Naka Y, Chowdhury NC, et al. The nitric oxide/cyclic GMP pathway in organ transplantation: Critical role in successful lung preservation. Proc Natl Acad Sci U S A 1994; 91: 12086.
34. Pinsky DJ, Oz MC, Koga S, et al. Cardiac preservation is enhanced in a heterotopic rat transplant model by supplementing the nitric oxide pathway. J Clin Invest 1994; 93: 2291.
35. Sasaki N, Sato T, Ohler A, et al. Activation of mitochondrial ATPdependent potassium channels by nitric oxide. Circulation 2000; 101: 439.
36. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001; 23: 291